EGFR-Mutated NSCLC: Integrating Emerging ELCC Data Into Treatment Sequencing
Medical artificial intelligence firm Lunit announced on September 8, 2026, that it will present three research abstracts leveraging its AI biomarker platform, Lunit Scope IO, at the 2026 World Conference on Lung Cancer (WCLC 2026).
Lunit presented three research abstracts at the 2026 World Conference on Lung Cancer (WCLC 2026) showcasing its AI biomarker platform, Lunit Scope IO. The studies focused on non‑small cell lung cancer (NSCLC) tissue analysis: 1) EGFR mutation subtypes (Exon 19 deletion, L858R, Exon 20 insertion) and their distinct tumor microenvironments; 2) predictive markers of pathological complete response (pCR) after neoadjuvant chemo‑immunotherapy; and 3) TP53 mutation status prediction based on immune‑activation signatures.
Evidence level: Sejtvonalas. Laboratóriumi sejtekben vizsgálták.
Related signals
- Telisotuzumab Vedotin + Osimertinib for Non‑Small Cell Lung Cancer
- Ramucirumab plus erlotinib in patients with untreated, EGFR‑mutated, advanced non‑small‑cell lung cancer (RELAY): a randomised, double‑blind, placebo‑controlled, phase 3 trial
- Recent advancements in lung cancer research: a narrative review
- Advances in Non-Small Cell Lung Cancer: Current Insights and Future Directions
- Structured proxy features for multimodal NSCLC survival prediction from pretreatment CT